Propel Bio Management, LLC Fulcrum Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q1 2024
A detailed history of Propel Bio Management, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 750,000 shares of FULC stock, worth $6.63 Million. This represents 4.12% of its overall portfolio holdings.
Number of Shares
750,000
Previous 750,000
-0.0%
Holding current value
$6.63 Million
Previous $5.06 Billion
39.85%
% of portfolio
4.12%
Previous 4.2%
Shares
1 transactions
Others Institutions Holding FULC
# of Institutions
136Shares Held
44.2MCall Options Held
3.12MPut Options Held
128K-
Rtw Investments, LP New York, NY5.85MShares$51.7 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$32.8 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$25.2 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$22.4 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$20.7 Million10.72% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $460M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...